{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:54:30Z","timestamp":1783090470397,"version":"3.54.6"},"reference-count":54,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T00:00:00Z","timestamp":1505088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2017,9,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Domperidone is a proposed treatment of orthostatic hypotension (OH) in Parkinson\u2019s disease (PD). However, domperidone use in PD is tempered by concerns regarding QT prolongation and ventricular tachyarrhythmia and sudden cardiac death (VT\/SCD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aim is to identify peer-reviewed studies in which either (1) the effect of domperidone on blood pressure in patients with PD, or (2) the adverse effects associated with domperidone use in PD patients has been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>PubMed, EMBASE, Medline and Scopus were searched using the terms Parkinson\u2019 s disease and domperidone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-two articles fulfilled the inclusion criteria. One study was a randomized placebo-controlled trial with domperidone administration independent of the commencement of dopaminergic medications. This study identified a non-statistically significant trend that domperidone may be beneficial for OH in PD. Several studies identified statistically significant differences in BP with domperidone in the setting of initiating dopaminergic medication. There is currently the most evidence to support domperidone use with apomorphine commencement. Studies reporting domperidone adverse effects in PD patients were largely retrospective or cross-sectional. The identified studies demonstrated that domperidone may cause QT prolongation and is associated with increased risk of VT\/SCD in PD patients with preexisting cardiac disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Domperidone may help to ameliorate OH associated with dopaminergic medications in PD, namely when used in conjunction with apomorphine. When considering whether to use domperidone in PD, factors that should be taken into account include pre-existing heart disease and drug interactions, as well as the impact of OH on mobility, cognition and quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jpd-171209","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T07:46:08Z","timestamp":1509522368000},"page":"603-617","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Domperidone for Hypotension in Parkinson\u2019s Disease: A Systematic Review"],"prefix":"10.1177","volume":"7","author":[{"given":"Stephen","family":"Bacchi","sequence":"first","affiliation":[{"name":"University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Chim","sequence":"additional","affiliation":[{"name":"University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Kramer","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Postuma","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.04.016"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26079"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.02.001"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.10.1461"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000842"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003452"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24877"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12478"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22537"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2013.00064"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.2015.1057504"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.5.835"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18003"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.2.3.393"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.2174\/1574886311308010009"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.01.040"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)91725-2"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6989(80)80108-1"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.6.662"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.44.5.426"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21428"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)91003-1"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.11.1644"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1007\/BF01819541"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(97)00032-1"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2001.104002092.x"},{"key":"ref028","first-page":"263","volume":"45","author":"Pollak P","year":"1987","journal-title":"Adv Neurol"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02571.x"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100030997"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12964"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.07.001"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2015.11.007"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92959-9"},{"issue":"3","key":"ref035","first-page":"3","volume":"25","author":"Van Dalem J","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.0703"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.07.019"},{"key":"ref038","first-page":"100","volume":"17","author":"Pinyopornpanish K","year":"2016","journal-title":"Thai J Gastroenterol"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120618"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(11)70603-4"},{"key":"ref041","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.11.1363"},{"key":"ref042","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.126"},{"key":"ref043","first-page":"391","volume":"76","author":"Lynch T","year":"2007","journal-title":"Am Fam Physician"},{"key":"ref044","unstructured":"U.S. Food and Drug Administration, How to request Domperidone for gastrointestinal disorders, U.S. Department of Health and Human Services, https:\/\/http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/approvalapplications\/investigationalnewdrugindapplication\/ucm368736.htm, Accessed 17 July 2017."},{"key":"ref045","unstructured":"European Medicines Agency, PRAC recommends restricting use of domperidone, http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2014\/03\/news_detail_002039.jsp&mid=WC0b01ac058004d5c1, Accessed 17 July 2017."},{"key":"ref046","unstructured":"European Medicines Agency, Assessment report: Domperidone-containing medicinal products, Accessed 16 July 2017."},{"key":"ref047","unstructured":"European Medicines Agency, CMDh confirms recommendations on restricting use of domperidone-containing medicines, http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2014\/04\/news_detail_002083.jsp, Accessed 15 July 3-28 2017."},{"key":"ref048","unstructured":"European Medicines Agency, Pharmacovigilance Risk Assessment Committee. (PRAC) - Minutes of the PRAC meeting on 11-14 January 2016, Accessed 16 July 2017."},{"key":"ref049","unstructured":"Domperidone Collaboration Study Group, A Post-Authorisation Safety Study. (PASS) Protocol: A Drug Utilisation Study of Domperidone in Europe Using Databases, Accessed 16 July 2017."},{"key":"ref050","unstructured":"Health Canada, Domperidone Maleate\u2014Association with Serious Abnormal Heart Rhythms and Sudden Death (Cardiac Arrest)\u2014For Health Professionals."},{"key":"ref051","unstructured":"Health Canada, Summary Safety Review. Domperidone - Serious abnormal heart rhythms and sudden death (cardiac arrest)."},{"key":"ref052","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afl175"},{"key":"ref053","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0360-0"},{"key":"ref054","doi-asserted-by":"publisher","DOI":"10.2174\/157488610791698334"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-171209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JPD-171209","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-171209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:46:00Z","timestamp":1777610760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JPD-171209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,11]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,9,11]]}},"alternative-id":["10.3233\/JPD-171209"],"URL":"https:\/\/doi.org\/10.3233\/jpd-171209","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,11]]}}}